Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1

The RV144 HIV vaccine trial included a recombinant HIV glycoprotein 120 (gp120) construct fused to a small portion of herpes simplex virus 1 (HSV-1) glycoprotein D (gD) so that the first 40 amino acids of gp120 were replaced by the signal sequence and the first 27 amino acids of the mature form of g...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: Wang, Kening, Tomaras, Georgia D., Jegaskanda, Sinthujan, Moody, M. Anthony, Liao, Hua-Xin, Goodman, Kyle N., Berman, Phillip W., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayapan, Sorachai, Kaewkungwal, Jaranit, Haynes, Barton F., Cohen, Jeffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2017
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599770/
https://ncbi.nlm.nih.gov/pubmed/28701403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00411-17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados